FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Latest Information Update: 04 Feb 2025
At a glance
- Drugs CDX 301 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Jan 2025 Status changed from active, no longer recruiting to completed.
- 08 Jun 2024 Planned End Date changed from 5 Oct 2022 to 1 Oct 2024.
- 08 Jun 2024 Status changed from completed to active, no longer recruiting.